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Inflammatory mediators in relation to the development 
of multiple organ failure in patients after severe blunt 
trauma
Rudi M. H. Roumen, MD, PhD; Heinz Redl, PhD; Günther Schlag, MD; Gertrud Zilow, MD;
Wolfgang Sandtner, MD; Wolfgang Koller, MD; Thijs Hendriks, PhD; R. Jan A. Goris, MD, PhD
Objective: To evaluate the posttraum atic 
course of several inflammatory mediators or 
markers (complement components C3, C3a, ter­
minal complement complex, thromboxane B2, 
C-reactive protein, elastase, and neopterin) in  
relation to the development of multiple organ 
failure and mortality.
Design: Prospective study of a selected pa­
tient group.
Setting: Surgical intensive care units in three 
European trauma hospitals.
Patients: Patients (n = 56) with severe blunt 
trauma (Injury Severity Score of ¡>33).
Interventions: Arterial blood samples were 
sequentially obtained.
M easurem ents an d  M ain Results: Non­
survivors (n = 8) had significantly higher circu­
lating C3a and elastase concentrations on the 
first postinjury day, compared with survivors 
(n = 48), No differences between these groups 
were found for terminal complement complex, 
thromboxane B„, C-reactive protein, and the 
neopterin/creatinine ratio.
Five patients died before day 5. Eighteen pa­
tients developed multiple organ failure, which 
was diagnosed from day 5 onward, leaving 33 
patients without m ultiple organ failure. The 
patients with subsequent multiple organ fail­
ure showed significantly higher mean circulat­
ing concentrations of C3a (914 ± 190 [ s e m ]  ng/
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mL), terminal complement complex (57 ± 17 U/ 
mL), and thromboxane B2 (275 ± 37 pg/mL) at 
the first postinjury day than the patients with­
out multiple organ failure (566 ±110 ng/mL, 27 ±
2 U/mL, and 169 ± 14 pg/mL, respectively). In 
patients w ith multiple organ failure, elastase 
concentrations were significantly higher on days 
2, 3, 4, and 5 postinjury. Neopterin/creatinine 
ratios, on the other hand, were significantly 
higher in patients with multiple organ failure 
when the multiple organ failure had already 
become established (on days 8 and 10).
Conclusion: In multiple trauma patients, ex­
cessive triggering of the inflammatory cascade— 
as expressed by complem ent activation and 
stimulation of neutrophils producing elastase— 
plays an important and early role in the devel­
opment of m ultiple organ failure. (Crit Care 
Med 1995; 23:474-180)
K e y  W o r d s : complement proteins; thrombox­
ane; C-reactive protein; neopterin; m ultiple 
trauma; multiple organ failure; critical illness; 
inflammation; neutrophils; adult respiratory 
distress syndrome
Death after multiple trauma occurs either immedi­
ately at the scene of the accident, or within hours after 
the event when patients are hospitalized (1). These 
fatalities are mainly due to the severity of injury or to 
direct complications from the primary injury. A third 
possibility is late death after days or even weeks, 
because of complications in remote organ systems not 
necessarily affected by the primary trauma. In the 
latter group, most patients die of adult respiratory 
distress syndrome (ARDS) and multiple organ failure 
syndromes that are thought to have one common 
pathophysiologic background (2, 3). This group is of 
special interest, not only because of the effect that 
these patients have on intensive care unit (ICU) utili­
zation, but also because the mechanisms leading to 
ARDS/multiple organ failure and subsequent death 
are unclear.
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In multiple trauma patients, head injury accounts 
for ~50% of deaths; hemorrhage accounts for ~10% to 
15% of deaths; and ARDS, multiple organ failure, and 
sepsis account for -30% to 35% of deaths (4, 5). The 
occurrence rate of multiple organ failure after multi­
ple trauma varies from 21% to 47% (4-7) and the 
mortality rate within this group varies from 20% to 
30%, depending on the patient populations studied 
and definitions used. Unfortunately, there is still no 
general consensus about the definition of this syn­
drome. Therefore, conclusions of various reports are 
difficult to compare and can lead to contradictory 
findings.
It remains puzzling why, in two patients with equiv­
alent preexisting conditions and similar trauma and 
treatment, one patient recovers within a few days and 
the other patient develops ARDS and multiple organ 
failure and subsequently dies. One hypothesis on this 
paradigm is that a varying inflammatory reaction to 
trauma may lead to a sequential autodestructive pro­
cess in various organ systems (2 ).
The present study on multiple trauma patients was 
performed to investigate the role of mediators and 
markers of the inflammatory cascades in relation to 
the development of multiple organ failure and mortal­
ity. The following parts of the inflammatory cascades 
were studied: complement activation; acute-phase 
protein synthesis; thromboxane production; and neu­
trophil and macrophage activation.
Complement Activation. Complement activation 
plays a central role in the inflammatory cascade, 
because of the release of anaphylatoxins that trigger a 
series of other biological events (8 ).
C3 is the initial key component that is activated 
either by the classical or the alternative pathway, the 
latter being the main route after trauma (8 ). From the 
activated split products, we chose C3a for measure­
ment, because other products are more rapidly cleared 
from the circulation (9). C3a and its ratio with C3 
(C3a/C3) has been shown to correlate positively with 
outcome in patients after trauma or septic shock (8-  
10). In addition, we measured the terminal comple­
ment complex, which is a complex formed by C5b, C6 , 
C7, C8 , and C9 and which indicates the activation of 
the terminal complement pathway (11). Since the 
generation of terminal complement complex requires 
activation of C5 to C5a and C5b, the terminal comple­
ment complex can be used as an indirect indicator of 
C5a formation (12).
C-Reactive Protein. The acute-phase reaction is a 
general and nonspecific response to most forms of 
infective and noninfective inflammatory processes, 
trauma, tissue necrosis, and neoplasms (13). C-reac- 
tive protein is a fast-reacting, acute-phase protein,
synthesized by hepatocytes under the influence of 
humoral mediators, such as prostaglandin EL or, espe­
cially, interleukin-6 (14). C-reactive protein may play 
a vital role as an opsonic protein in the immediate 
postinjury period, when complement is consumed (16). 
C-reactive protein probably acts primarily as a protec­
tive mechanism, but in some circumstances, C-reac­
tive protein may also initiate or exacerbate inflamma­
tory lesions (13). Some studies (16,17) showed a positive 
correlation between the severity of (surgical) trauma 
and concentrations of C-reactive protein.
Thromboocane B2. Eicosanoids, with a broad spec­
trum of biological activities, represent a class of lipid 
mediators that are derived from polyunsaturated fat­
ty acids (18). The major natural source is arachidonic 
acid. Enzymatic catalyzation of arachidonic acid leads 
to either prostaglandins and thromboxanes by the 
cyclooxygenase pathway, or to leukotrienes by the 
lipoxygenase pathway. In the present study, throm­
boxane B2—which is the inactive metabolite of the 
main biologically active product thromboxane A^ , with 
strong vasoactive and platelet-stimulatory effects (18)— 
was chosen for evaluation of the cyclooxygenase path­
way. Many different inflammatory triggers (e.g., al­
lergic reactions, toxic oxygen radicals, endotoxin) and 
especially septic or circulatory shock are associated 
with enhanced eicosanoid formation (18,19).
Elastase. There is much evidence that neutrophils 
play a major part in triggering complications in septic 
or posttraumatic patients (6 ,9). The enzyme elastase 
is released from stimulated neutrophils at the site of 
injury, infection, or inflammation and can cause tis­
sue damage and subsequent organ dysfunction. By 
measuring the complex of elastase with its inhibitor 
«j-proteinase (elastase-oq proteinase inhibitor com­
plex) in plasma, the degree of neutrophil activation 
can be quantified (20 , 21).
Neopterin. There is increasing evidence that acti­
vated macrophages play a key role in the auto­
destructive inflammatory response to traumatic or 
septic events (3). After immune stimulation (e.g., by 
endotoxin or 7-interferon activated macrophages pro­
duce and excrete the inactive metabolite neopterin 
(22). Neopterin is cleared from the circulation in a 
creatinine-like manner and can be measured in blood 
as well as in urine (23,24), To correct for possible 
renal insufficiency, we therefore used the neopterin/ 
creatinine ratio to grade macrophage activation.
MATERIALS AND METHODS
During a 2-yr period, data from 56 multiple trauma 
patients were prospectively collected as part of a
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multicenter trial on the evaluation of inflammatory 
mediators and scoring systems (25). Patients with 
blunt trauma were admitted to three trauma hospi­
tals in Europe (University Hospital, Innsbruck, Aus­
tria; University Hospital, Nijmegen, The Netherlands; 
Lorenz Bohler Hospital, Vienna, Austria). Patients 
were included in the study if the Injury Severity Score 
(26) calculated from the Hospital Trauma Index (27) 
was ¿ 33 , which represents at least two severe lesions 
in different body regions or one severe and two major 
lesions in three different regions.
Extensive data collection was performed on hospi­
tal admission to the hospital and daily during the ICU 
admission, for <2 wks after injury. Informed consent 
was obtained from the patients’ relatives before the 
study, which was approved by the local Ethics
Committees.
Blood sampling at the ICU was done daily in the 
first week and every other day in the second week. 
Biochemical measurements were performed using the 
following techniques. C3a was determined by enzyme- 
linked immunosorbent assay technique, according to 
Zilow et al (28). C3 was determined by radio- 
immunodiffusion (NOR-Partigen, Behring Diagnos­
tics, Marburg, FRG) and terminal complement com­
plex, according to Deppisch et al (29). C-reactive protein 
was determined by an immunoturbidometric assay 
(Orion Diagnostica, Espoo, Finland). Thromboxane B2 
was determined by radioimmunoassay, as described 
by Flynn et al (30). Elastase-otj proteinase inhibitor 
complex was determined by enzyme-linked immun­
osorbent assay (Merck, Darmstadt, FRG). Neopterin 
was determined using a radioimmunoassay (Henning, 
Berlin, FRG), with neopterin/creatinine ratios ex­
pressed as p.mol/mol.
Multiple organ failure and mortality rate were the 
focus of our inflammatory mediator study. Survivors 
were defined as patients discharged from the hospital 
alive; nonsurvivors were patients who died in the 
hospital because of any posttraumatic complication.
For all patients, Acute Physiology and Chronic 
Health Evaluation II score (31) and multiple organ 
failure score (2,32) were calculated daily. For deter­
mination of the multiple organ failure score and Acute 
Physiology and Chronic Health Evaluation II score, 
the most deranged values of the various contributing 
parameters of each day were used.
The multiple organ failure score, according to Goris 
et al. (2 ), grades organ function as normal (0 point), 
moderately disturbed (1 point), or severely disturbed 
(2 points), with a maximum of 14 points in seven main 
organ systems (Table 1). Multiple organ failure was 
defined as an average multiple organ failure score of 
>4 from day 5 to day 14 (25). Statistical analyses were
Table 1. Multiple organ failure (MOF) score. MOF score is total of 
seven organ failure scores, with a maximum of 14 points
Organ
System
MOF Score
1 2
Pulmonary Mech. ventilation with Mech. ventilation with
PEEP <10 cm H20, PEEP >10 cm HaO,
Fio„ S0.4 Fio.. >0.4
Cardiac Hypotension >100
mU
Hypotension ¿100
mm Hg; dopamine mm Hg; dopamine
<10 pg/kg/min; >10 pg/kg/min;
nitroglycerin £20 jag/ nitroglycerin >20 pg/
kg/min kg/min
Renal Serum creatinine 
£2 mg/dL 
(>176.8 pmol/L)
Dialysis
Hepatic Serum bilirubin Serum bilirubin
>2 mg/dL (>34.2 pmol/L) >6 mg/dL (>102.6
or SGOT >25 U/L pmol/L) or SGOT ¿50
U/L
Hematologic Platelets <50 x 10® Disseminated intravas-
cells/L and/or WBCs cular coagulation;
£30 x 109 cells/L WBCs <2.5 x 10» 
cells/L or >60 x 
10flcells/L
GI Acalculous cholecystitis Perforated gallbladder
Stress ulcer Bleeding from ulcer >2 
units of blood/24 hrs; 
necrotizing enterocoli­
tis; pancreatitis
Central Diminished Severely disturbed
nervous responsiveness responsiveness and/or 
diffuse neuropathy
MOF Score 0, no failure; MOF Score 1, moderate failure; MOF 
Score 2, severe failure; mech., mechanical; PEEP, positive end- 
expiratory pressure; SGOT, serum glutamic-oxaloacetic 
transaminase; WBCs, white blood cells; GI, gastrointestinal.
performed using the Wilcoxon two-sample test for 
comparison between groups. A p < .05 was considered 
significant.
RESULTS
Fifty-six patients entered the study (ten female and 
46 male). The mean age was 33 yrs (range 14 to 71). 
The mean Injury Severity Score of all patients was 46 
± 10 ( s d ) (range 33 to 75). The mortality rate was 14%, 
as eight patients died. Table 2 shows the cause of 
death and the day after admission that these patients 
died. Mean Injury Severity Score of survivors was 44 
± 10; the mean Injury Severity Score of nonsurvivors 
was 55 ± 10 (p < .01). Because five patients died early 
(within 3 days), we only provide data concerning in­
flammatory mediators in relation to the mortality rate 
of the first day of admission. Differences between 
survivors and nonsurvivors for the various mediators 
are shown in Table 3. On day 1, only complement 
activation (expressed by C3a/C3 ratios) and elastase
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Table 2. Injury severity scores (ISS), cause, and day of death in the 
eight patients who died
Patient ISS Day Cause
1 50 1 Severe thoracic injury, ruptured lungs
2 38 3 Brain death
3 75 3 Severe thoracic injury and brain death
4 57 3 Brain death
5 57 3 Coagulopathy, ARDS + acute renal 
failure (early MOF)
6 57 6 Acute renal failure and brain death
7 50 9 MOF
8 57 37 MOF
ARDS, adult respiratory distress ; MOP
organ
Table 3. Inflammatory mediators (mean ± sd) in survivors (n = 48) 
and nonsurvivors (n = 8), as determined on the first day after injury
Mediator Survivors Nonsurvivors p Value
C3 (mg/mL) 0.67 bfc 0.31 0.71 0.28 .32
C3a (ng/mL) 604 ± 571 1331 619 .01“
C3a/C3 x 1000 0.96 ± 0.79 3.23 dt 4.24 <.001'’
TCC (U/mL) 36 ± 34 53 28 .07
CRP (mg/L) 55 ± 51 33 24 .41
TxB,, (pg/mL) 194 ± 92 237 bt 155 .19
Elastase ( ng/mL) 539 db 337 1006 ± 287 .03"
Neop/creat
(pmol/mol) 837 488 906 ± 476 .71
C, complement component; TCC, 
plex; GRP, C-reactive protein; TxBa, 
neopterin/creatinine ratio.
"p < .05; l'p < .01, by Wilcoxon two-
complement com* 
B,,; neop/c:reat,
e test.
concentrations were significantly different between 
survivors and nonsurvivors. The differences for the 
C3a/C3 ratios were mainly caused by significantly 
increased concentrations of C3a in the nonsurvivors. 
Terminal complement complex showed a tendency
toward higher nonsurvivors com-
survivors (p
21'.\ V before day 5, 51
were £ iff ;for classification
without multiple organ 
multiple organ was
Figure 1 shows the mean ± sem
2 51 patients, 
in 18 cases.
3s of six mediators
during the 2-wk study period in patients with and 
without multiple organ failure. On day 1, terminal 
complement complex, thromboxane B2, and G3a con­
centrations were 
multiple organ failure, while C-reactive protein con-
centration was on 1 2 . most
protracted differences between patients with and with­
out multiple organ failure were found for elastase.
Concentrations of elastase were si
in patients with multiple organ failure for practically 
the whole first week after injury. Neopterin/creatinine
ratios did not show any significant difference between 
both groups during the first week. However, signifi­
cantly higher neopterin/creatinine ratios were found 
in patients with multiple organ failure on day 8 (p = 
.04) and on day 10 (p = .005), while there was an
indication of significance on day 12 (p .06).
DISCUSSION
In the present report, we prospectively evaluated 
inflammatory mediators in relation to subsequent 
multiple organ failure and mortality. We studied a 
homogeneous group of severely traumatized patients, 
who had at least two severe or one severe plus two 
major lesions in different body regions (Injury Sever­
ity Score of ¿33 ). This finding contrasts with the 
results of most other reports (7,9,12, 33), which eval­
uated a much wider range of “multiple”-injured pa­
tients, including those patients with an Injury Sever­
ity Score of <18 points. In the present study, a smaller 
range of Injury Severity Scores was evaluated; hence, 
the differences between groups in the present study 
will become less easily evident. On the other hand, if 
differences between groups occur, they could be 
pathophysiologically more relevant.
Complement and neutrophil activation, expressed 
by C3a or C3a/C3 ratios and elastase concentrations, 
respectively, appeared to be the most significant medi­
ators for differentiation between survivors and 
nonsurvivors. This finding is in agreement not only 
with the results of other trauma patient studies, but 
also with results from studies involving patients un­
dergoing major elective surgery and patients with
sepsis (8 ,10-12, 20, 21, 34, 35).
The most important finding of our study is that
e were
tions of complement activation 
complement complex), as well as thromboxane 
concentrations, on the first postinjury day in patients
2
those patients without subsequent multiple organ fail­
ure. Moreover, elastase concentrations were signifi­
cantly increased practically the entire first week in
the patients with subsequent organ failure.
In contrast, C-reactive protein concentrations were
higher patients without 
r is not in £ a previ-
mcrease in
and without multiple organ failure during the 
first 4 days after injury, with a significant increase in 
C-reactive protein concentrations in 
failure patients from day 5 onward. We also could not 
demonstrate a positive correlation between severity of
478 C ritical  C a r e  M e d ic in e M a r c h , 1995
400
300
mmJ
.E
D>
CL
CM
DO
I—
200 -
100 -
0
1000
mhI
,E
j? 800
2000
X
0)
Q .
Eo
o
CL
600 -
üi
0>ay
cu
400 -
w
LU
200
0
1500
1200
co
' 900 ~
ro
0)
i _O
Q .OO)C
600
300
0
1 2 3 4 5 6 8 10 12 14
day
£
o>
<0
COO
1000 -
0
200
£
3  100
ooj .1rr
0
200
D)
E 100 -
ûu
cco
0 m t* ni Mimmpnw 1 1 i
1 2 3 4 5 6 8 10 12 14
day
Figure 1. Mean ± sem  values of C3a, terminal complement complex (TCC), C-reactive protein (CRP), thromboxane Ba (TxliJ, e 
and neopterin/creatinine (neoplcreat) during a 2-wk intensive care unit observation period in 51 multiple trauma patients with 
organ failure {solid line, n = 18) and without multiple organ failure (broken line , n = 33). The p values are indicated by asterisks 
¿ p  < .10; "jo < .05; and **p < .01, by the Wilcoxon teat.
injury, as expressed by Injury Severity Score (data not 
shown), and C-reactive protein response, while other 
reports (15-17) showed that the magnitude of (surgi­
cal) trauma correlated well with the concentrations of 
C-reactive protein production. A possible explanation 
could be that the patients in the present study all had 
such severe trauma that this situation led to similar 
C-reactive protein concentrations according to the “all 
or nothing phenomenon” theory of Colley et al (36). 
On the other hand, it remains questionable to what 
extent liver damage and hepatic insufficiency may
contribute to the initial lower C-reactive protein 
production in patients developing multiple organ 
failure.
The role of the prostanoid thromboxane B2 in the 
development of ARDS and multiple organ failure re­
mains unclear. Some authors (19, 37) reported a posi­
tive correlation with subsequent ARDS, while others 
(38) could not confirm this finding. We could only 
demonstrate a significantly higher concentration of 
thromboxane B2 on the first posttraumatic day in 
patients with subsequent multiple organ failure.
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Neopterin concentrations in blood and urine have 
been shown to predict the outcome of patients with 
viral infections (including acquired immunodeficiency 
syndrome), autoimmune diseases, and graft vs. host 
reactions (39). Also, increased concentrations of 
neopterin are associated with poor outcome in multi­
ple trauma and sepsis patients (6, 7, 39). Since 
neopterin is exclusively eliminated by the kidneys in a 
creatinine-like manner (23,24), plasma neopterin con­
centrations should be used in reference to creatinine. 
Nast-Kolb et al. (6) concluded in their study on 69 
multiple trauma patients that neopterin was a reli­
able parameter in predicting subsequent organ failure 
from days 2 to 5, but after this period, increased 
neopterin concentrations were mainly caused by re­
tention due to renal insufficiency (6). In the present 
series, we therefore used the corrected neopterin con­
centrations during the entire observation period. We 
could only demonstrate a significant increase of the 
neopterin/creatinine ratio in multiple organ failure 
patients in the second week. This finding is in agree­
ment with the finding of Nathan (40), who concluded 
that it apparently takes several days for macrophages 
after activation to fully develop their inflammatory 
capacity.
The present data support the view that comple­
ment activation plays a central and early role in the 
inflammatory cascade, leading to complications and 
poor outcome in multiple trauma patients. Comple­
ment activation is fundamental for bacterial 
opsonization and recruitment of inflammatory cells by 
chemoattraction. Complement activation elicits the 
release of lysosomal enzymes, such as elastase, and 
oxygen radicals by means of neutrophils, thus contrib­
uting to the defense against microorganisms, but also 
leading to cell and tissue damage that ultimately may 
result in organ failure (11, 34). Elastase appears to be 
not only a marker of severity of injury and a mediator 
leading to proteolysis of a great variety of normal 
tissue substances, but also a factor significantly corre­
lating with final outcome.
The present study underlines the importance of the 
complement system and neutrophil activity in the 
early posttraumatic phase, not only in terms of mor­
tality, but also in terms of the major complicating 
syndrome, multiple organ failure. Prevention of a 
continuous activation of the complement system and 
ongoing triggering of neutrophils (e.g., by adequate 
treatm ent of hypovolemic shock and optimal 
reoxygenation, thorough excision of necrotic tissue, 
prevention of compartment syndrome, etc.) are key 
goals in the early management of multiple trauma 
patients. Finally, these data support the hypothesis 
that multiple organ failure is the result of an excessive,
uncontrolled, autodestructive activation of inflamma­
tory cells and mediators (2).
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